NASDAQ:KZIA Kazia Therapeutics (KZIA) Stock Price, News & Analysis → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Free KZIA Stock Alerts $0.38 0.00 (0.00%) (As of 04/22/2024 ET) Add Compare Share Share Today's Range$0.37▼$0.4150-Day Range$0.20▼$0.4652-Week Range$0.19▼$1.49Volume118,916 shsAverage Volume757,531 shsMarket Capitalization$6.16 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Kazia Therapeutics alerts: Email Address Kazia Therapeutics MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy1.59% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.16Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.40) to ($0.33) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.32 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Kazia Therapeutics. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.59% of the outstanding shares of Kazia Therapeutics have been sold short.Short Interest Ratio / Days to CoverKazia Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Kazia Therapeutics has recently increased by 6.88%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldKazia Therapeutics does not currently pay a dividend.Dividend GrowthKazia Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for KZIA. Previous Next 2.1 News and Social Media Coverage News SentimentKazia Therapeutics has a news sentiment score of -0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.48 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Kazia Therapeutics this week, compared to 0 articles on an average week.Search Interest1 people have searched for KZIA on MarketBeat in the last 30 days. MarketBeat Follows6 people have added Kazia Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Kazia Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.00% of the stock of Kazia Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 30.89% of the stock of Kazia Therapeutics is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Kazia Therapeutics are expected to grow in the coming year, from ($0.40) to ($0.33) per share.Price to Book Value per Share RatioKazia Therapeutics has a P/B Ratio of 0.75. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About Kazia Therapeutics Stock (NASDAQ:KZIA)Kazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma, diffuse intrinsic pontine glioma/advanced solid tumors, atypical teratoid rhabdoid tumor, brain metastases, triple negative breast cancer, and primary central nervous system lymphoma. It is also developing EVT801, a small molecule targeted therapeutic vascular endothelial growth factor receptor 3 inhibitor. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. The company was incorporated in 1994 and is based in Sydney, Australia.Read More KZIA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KZIA Stock News HeadlinesApril 16, 2024 | americanbankingnews.comKazia Therapeutics Limited (NASDAQ:KZIA) Sees Significant Increase in Short InterestMarch 20, 2024 | morningstar.comKazia Therapeutics Ltd ADR KZIAApril 23, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. March 16, 2024 | finance.yahoo.comKZIA Apr 2024 2.500 callMarch 13, 2024 | prnewswire.comKazia announces presentation of new data at AACR Annual MeetingFebruary 21, 2024 | msn.comWhat's Going With Australia-Based Cancer Firm Kazia Therapeutics On Wednesday?February 21, 2024 | finanznachrichten.deKazia Therapeutics Limited: Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary EndpointFebruary 21, 2024 | finance.yahoo.comKazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary EndpointApril 23, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. February 21, 2024 | prnewswire.comKazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary EndpointFebruary 19, 2024 | thestreet.comKazia Therapeutics LimitedFebruary 14, 2024 | wsj.comKazia Therapeutics Ltd. ADRFebruary 13, 2024 | nasdaq.comViking Therapeutics, Inc. Common Stock (VKTX)January 18, 2024 | finance.yahoo.comKAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTSDecember 15, 2023 | msn.comKazia Therapeutics files to sell 591,697 ADSs for holdersDecember 5, 2023 | finance.yahoo.comKazia Therapeutics Announces Closing of $2 Million Registered Direct OfferingDecember 1, 2023 | marketwatch.comKazia Therapeutics Shares Tumble on $2 Million Direct OfferingDecember 1, 2023 | markets.businessinsider.comKazia Therapeutics Announces Registered Direct Offering - Quick FactsDecember 1, 2023 | finance.yahoo.comKazia Therapeutics Announces $2 Million Registered Direct OfferingNovember 29, 2023 | msn.comKazia stock jumps after proposed license deal for paxalisib outside oncologyNovember 29, 2023 | markets.businessinsider.comKazia Therapeutics Enters Non-binding LOI For Paxalisib Rights Outside Of OncologyNovember 29, 2023 | marketwatch.comKazia Therapeutics Signs Letter of Intent for Paxalisib Development, CommercializationNovember 29, 2023 | finance.yahoo.comKAZIA ANNOUNCES NON-BINDING LETTER OF INTENT FOR THE PROPOSED GRANTING OF RIGHTS TO DEVELOP AND COMMERCIALIZE PAXALISIB OUTSIDE OF ONCOLOGYNovember 21, 2023 | finance.yahoo.comKAZIA PROVIDES OVERVIEW OF PAXALISIB RELATED PRESENTATIONS FROM THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETINGNovember 20, 2023 | msn.comKazia Therapeutics gets deficiency notice from NasdaqNovember 18, 2023 | finance.yahoo.comKazia Therapeutics Limited's (NASDAQ:KZIA) large institutional owners must be happy as stock continues to impress, up 28% over the past weekNovember 15, 2023 | finance.yahoo.comKAZIA ANNOUNCES THE RELEASE OF PNOC022 CLINICAL STUDY ABSTRACT HIGHLIGHTING PAXALISIB IN DIFFUSE MIDLINE GLIOMA PATIENTS AHEAD OF THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETINGSee More Headlines Receive KZIA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kazia Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/22/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:KZIA CUSIPN/A CIK1075880 Webwww.kaziatherapeutics.com Phone(129) 472-4101Fax61-2-9476-0388Employees2,021Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.71 Quick RatioN/A Sales & Book Value Annual Sales$20,000.00 Price / Sales308.01 Cash FlowN/A Price / Cash FlowN/A Book Value$0.50 per share Price / Book0.75Miscellaneous Outstanding Shares16,340,000Free Float16,178,000Market Cap$6.16 million OptionableOptionable Beta2.12 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. John Edwin Friend II (Age 54)M.D., CEO, MD & Director Comp: $707.94kMs. Gabrielle Heaton BBUS (ACC)CPA, Principal Accounting Officer, VP of Finance & Administration and Principal Financial OfficerMs. Anna SandhamCompany SecretaryKey CompetitorsEnsysce BiosciencesNASDAQ:ENSCPetros PharmaceuticalsNASDAQ:PTPIArtelo BiosciencesNASDAQ:ARTLPaxMedicaNASDAQ:PXMDSoligenixNASDAQ:SNGXView All CompetitorsInstitutional OwnershipPlatinum Investment Management Ltd.Bought 1,821,887 shares on 2/14/2024Ownership: 11.150%Armistice Capital LLCBought 2,475,555 shares on 2/13/2024Ownership: 15.150%View All Institutional Transactions KZIA Stock Analysis - Frequently Asked Questions How have KZIA shares performed in 2024? Kazia Therapeutics' stock was trading at $0.4395 at the beginning of the year. Since then, KZIA stock has decreased by 14.2% and is now trading at $0.3770. View the best growth stocks for 2024 here. Are investors shorting Kazia Therapeutics? Kazia Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 259,500 shares, an increase of 6.9% from the March 15th total of 242,800 shares. Based on an average trading volume of 838,400 shares, the days-to-cover ratio is currently 0.3 days. View Kazia Therapeutics' Short Interest. What other stocks do shareholders of Kazia Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Kazia Therapeutics investors own include Fulcrum Therapeutics (FULC), Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Idera Pharmaceuticals (IDRA), MEI Pharma (MEIP), Pfizer (PFE), Telesis Bio (TBIO), VYNE Therapeutics (VYNE) and Allena Pharmaceuticals (ALNA). How do I buy shares of Kazia Therapeutics? Shares of KZIA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:KZIA) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Reporttop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyIncredible Opportunity to Retire FAST!Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryThe #1 Crypto for 2024InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kazia Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
